Instrument NameAstrazeneca Plc ADRInstrument Symbol(AZN-Q)

Instrument ExchangeNASDAQ

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is the current enthusiasm for all things artificial intelligence (AI)-related. Some of those high valuations are because AI has sent some...

AstraZeneca just released some encouraging data about its weight loss drug candidates.

AZN earnings call for the period ending September 30, 2024.

Monday U.S. Featured Earnings Monday.Com Ltd (NASDAQ: MNDY) (Q3) EPS of four cents, compared ...

The Anglo-Swedish company, which has invested heavily in the world’s No. 2 pharmaceuticals market, said last week that its China president, Leon Wang, was under investigation and that the drugmaker would cooperate with authorities

The price could be right for these stocks.

In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to disrupt themselves.

Investors seeking AI-led drug development opportunities can consider this top-rated biotech stock under $5.

Investing in the most popular players in the space isn't the only valid approach.

Global Markets Canadian Markets Canada’s main stock index, the TSX experienced a slight decline on Monday as investors reassessed expectations for a potential interest rate cut by the Federal Reserve in November, and its impact on Canadian financial markets and the Bank of Canada’s future rate policy settings . This...

Its alliance with a successful foreign biotech could be decisive for the stock.

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

Cancer, a complex disease characterized by uncontrolled cell growth and proliferation, is often rooted in defects within DNA repair mechanisms. Normally, cells possess intricate repair pathways that rectify mutations or damage caused by environmental factors or internal processes. However, when these pathways malfunction, either due to genetics or acquired mutations,...

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines...

The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines is paramount. DNA-damage response (DDR)-based therapies, which target cancer cells' repair mechanisms, are emerging...

/CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new...

Shares of AstraZeneca (AZN) are down 5% after the British pharmaceutical company reported disappointing ...

These stocks are all up more than 20% this year.

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma market will be worth $39B in sales by 2032.

The winners of today might not compete in the lucrative new segment of tomorrow.

These stocks arguably deserve more respect from investors.

The British drugmaker's Q2 results were good, but seemingly not good enough for many investors.

AZN earnings call for the period ending June 30, 2024.

Second-quarter profit was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said